Skip to main content

Cardlytics Inc

For the period ended Dec 31, 2024. Filed Mar 12, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 12, 2025

CDLX$1.63-10.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 15. Exhibits, Financial Statement Schedules

ITEM 15. EXHIBIT AND FINANCIAL STATEMENT SCHEDULES

(a)The following documents are filed as part of this Annual Report:

(i)Consolidated Financial Statements and Reports of Independent Registered Public Accounting Firm are shown in the Index to Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.

(ii)All financial statement schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.

(iii)Exhibits are incorporated herein by reference or are filed with this Annual Report as indicated below.

(b)Exhibits:

Incorporated by Reference
ExhibitExhibit DescriptionSchedule/FormFileNumberExhibitFiling Date
3.1Amended and Restated Certificate of Incorporation of the RegistrantS-1333-2225313.21/12/2018
3.2Amended and Restated Bylaws of the RegistrantS-1333-2225313.41/12/2018
4.1Form of Common Stock Certificate of the RegistrantS-1/A333-2225314.11/29/2018
4.2Description of Cardlytics, Inc. Common Stock10-K001-383864.33/3/2020
4.3Indenture, dated as of September 22, 2020, by and between the Registrant ant U.S. Bank National Association, as Trustee.8-K001-383864.19/22/2020
4.4Form of Global Note, representing the Registrant’s 1.00% Convertible Senior Notes due 2025 (included as Exhibit A to the Indenture filed as Exhibit 4.4)8-K001-383864.29/22/2020
4.5Indenture, dated as of April 1, 2024, by and between the Registrant ant U.S. Bank National Association, as Trustee.8-K001-383864.14/1/2024
4.6Form of Global Note, representing the Registrant’s 4.25% Convertible Senior Notes due 2029 (included as Exhibit A to the Indenture filed as Exhibit 4.6)8-K001-383864.24/1/2024
10.1Office Lease Agreement, dated as of August 5, 2013, by and between the Registrant and Jamestown Ponce City Market, L.P.S-1333-22253110.121/12/2018
10.2†2008 Stock Plan and Forms of Option Agreement, Notice of Stock Option Grant, Exercise Notice, Restricted Stock Unit Notice and Restricted Stock Unit Agreement thereunder, as amended to dateS-1/A333-22253110.11/29/2018
10.3†2018 Equity Incentive Plan and Forms of Stock Option Agreement, Notice of Exercise and Stock Option Grant Notice thereunderS-1/A333-22253110.21/29/2018
10.4†2018 Employee Stock Purchase PlanS-1/A333-22253110.31/29/2018
10.5†Form of restricted securities unit award of the Registrant under 2018 Equity Incentive PlanS-1333-22253110.81/12/2018
10.6†Form of Indemnity Agreement by and between the Registrant and each of its directors and executive officersS-1333-22253110.91/12/2018
10.7^Software License, Customization and Maintenance Agreement, dated as of November 4, 2010 by and between the Registrant and Bank of America, N.A., as amended to dateS-1333-22253110.161/12/2018
10.8^Master Agreement and Schedule #1 to the Master Agreement, dated May 3, 2018 and May 7, 2018, respectively, by and between the Company and JPMorgan Chase Bank, National Association10-Q001-3838610.18/14/2018
10.9^2018 Amendment to Schedule #1 to the Master Agreement, dated October 23, 2018, by and between the Registrant and JPMorgan Chase Bank, N.A.10-K001-3838610.223/3/2020
10.10^Second Amendment to Schedule #1, dated June 4, 2020, among Cardlytics, Inc. and JPMorgan Chase Bank, National Association10-Q001-3838610.18/4/2020
10.11^2020 Amendment to General Services Agreement, dated December 2, 2020, by and between the Registrant and Bank of America, N.A.10-K001-3838610.273/3/2021
10.12Consent to Loan and Security Agreement, dated as of March 5, 2021, by and among Cardlytics, Inc., as Borrower, BSpears Merger Sub II, LLC, as additional borrower, and Pacific Western Bank, as Lender10-Q001-3838610.15/4/2021
10.13^Agreement and Plan of Merger, dated April 12, 2021, by and among Cardlytics, Inc., Bridg, Inc., Mr. T Merger Sub, Inc., and Shareholder Representative Services LLC8-K001-3838610.111/18/2022
10.14^General Service Agreement dated as of July 7, 2022 by and between the Registrant and Bank of America, N.A.10-Q001-3838610.28/2/2022
10.15^Statement of Work Agreement dated as of July 7, 2022 by and between the Registrant and Bank of America, N.A.10-Q001-3838610.38/2/2022
10.16†Offer Letter Agreement between Karim Temsamani and Cardlytics, Inc.10-Q001-3838610.211/1/2022
10.17†Severance Agreement between Karim Temsamani and Cardlytics, Inc.10-Q001-3838610.311/1/2022
10.18†Severance Agreement between Nick Lynton and Cardlytics, Inc.10-Q001-3838610.411/1/2022
10.19†2022 Inducement Plan10-Q001-3838610.711/1/2022
10.20†Form of option grant notice and agreement under 2022 Inducement Plan10-Q001-3838610.811/1/2022
10.21†Form of restricted stock unit grant notice and agreement under 2022 Inducement Plan10-Q001-3838610.911/1/2022
10.22†Offer Letter Agreement between Amit Gupta and Cardlytics, Inc.10-K001-3838610.413/1/2023
10.23†Severance Agreement between Amit Gupta and Cardlytics, Inc.10-K001-3838610.413/1/2023
10.24†Amendment to Inducement Plan10-K001-3838610.413/1/2023
10.25^Amendment No. Two to Office Lease Agreement dated as of April 23, 2023, by and between the Registrant and Jamestown Ponce City Market, L.P., as amended to date10-Q001-3838610.45/4/2023
10.26Second Amendment to Inducement PlanS-8001-383864.87/18/2023
10.27^Third Amendment to Schedule #1, dated June 29, 2023, to the Master Agreement by and between the Registrant and JPMorgan Chase Bank, N.A.10-Q001-3838610.18/1/2023
10.28†Offer Letter Agreement between Alexis DeSieno and the Registrant dated June 20, 202310-Q001-3838610.28/1/2023
10.29†Separation Pay Agreement between Alexis DeSieno and the Registrant, dated July 13, 2023.10-Q001-3838610.38/1/2023
10.30Cooperation Agreement, dated as of September 19, 2023, by and among Cardlytics, Inc. and the investors named therein8-K001-3838610.19/19/2023
10.31Settlement Agreement by and between the Company and Shareholder Representative Services LLC, dated as of January 25, 202410-K001-3838610.53/14/2025
10.32Amended Non-Employee Director Compensation Plan10-K001-3838610.533/14/2025
10.33Work Order between the Company and American Express Travel Related Services Company dated March 14, 2024 to Master Hosted Services Agreement10-Q001-3838610.45/8/2024
10.34^Statement of Work Change Order dated May 24, 2024, between the Registrant and Bank of America, N.A.10-Q001-3838610.18/7/2024
10.35Offer Letter between Amit Gupta and the Registrant, dated August 21, 2024.10-Q001-3838610.111/6/2024
10.36Amended and Restated Loan and Security Agreement dated as of September 30, 2024, by and among Cardlytics, Inc., as Borrower and Banc of California, as Lender10-Q001-3838610.311/6/2024
10.37*Assumption Agreement and First Amendment to Loan and Security Agreement, dated as of December 6, 2024, by and among Cardlytics, Inc., as Borrower and Banc of California, as Lender
10.38*^Assumption Agreement and Second Amendment to Loan and Security Agreement, dated as of January 27, 2025, by and among Cardlytics, Inc., as Borrower and Banc of California, as Lender
10.392024 Bonus Plan of the Registrant
19.1Insider Trading Policy
21.1Subsidiaries of the Registrant10-Q001-3838621.18/14/2018
23.1*Consent of Deloitte & Touche LLP, independent registered public accounting firm
31.1*Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
97.1Amended and Restated Policy for Recoupment of Incentive Compensation, adopted on October 2, 202310-K001-3838697.13/14/2025
101.insXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.schXBRL Taxonomy Schema With Embedded Linkbase Document
104.0Cover page formatted as Inline XBRL and contained in Exhibit 101
  • Filed herewith

** Furnished herewith

^ Certain portions of this exhibit, indicated by asterisks, have been omitted pursuant to Item 601(b)(10) of Regulation S–K because they are not material and would likely cause competitive harm to the registrant if publicly disclosed.

† Indicates management contract or compensatory plan

Confidential treatment has been granted from the Securities and Exchange Commission as to certain portions of this document

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.